Cerulean Pharma Inc.

Otsuka Pharmaceutical Co. Ltd. has entered into a definitive agreement to pay around $430m in cash for the private US antibody technology venture Visterra Inc. , in a step the major Japanese pharma

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in

Start-up RallyBio Inc. , which launched on April 25 with $37m in Series A venture capital, is starting out with a dream team of executives with experience developing, launching and marketing therapie

IN VITRO DIAGNOSTICS Financings Biocept Inc. Biocept Inc. (blood-based molecular diagnostics for solid tumors) netted $8.7mm through the sale of 4.3mm common shares at $2.15 (a slight discount) to